LY3537031 for Obesity

Phase 1

Recruiting

Research Sponsored by Eli Lilly and Company

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Weigh 60 kg (80 lbs) or more at screening for Parts B and C

Be older than 18 years old

Must not have

Have undergone any form of bariatric surgery

Timeline

Screening 3 weeks

Treatment Varies

Follow Up predose on day 1 through week 20

Summary

"This trial will test a new drug called LY3537031 in overweight/obese individuals in Part A and healthy individuals in Parts B and C. Part C will specifically focus on Japanese and Chinese participants

Who is the study for?

This clinical trial is for overweight or obese individuals, as well as healthy participants including specifically Japanese and Chinese individuals in one part of the study. The main goal is to test the safety and tolerability of a new drug called LY3537031.

What is being tested?

The trial tests LY3537031 against a placebo (a substance with no therapeutic effect) across three parts: Part A focuses on overweight/obese participants, while Parts B and C focus on healthy subjects, including specific ethnic groups in Part C.

What are the potential side effects?

While not explicitly listed here, common side effects may include reactions at the injection site, gastrointestinal issues, fatigue, headaches, or allergic responses. Specific side effects will be monitored through blood tests and other health checks.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I weigh at least 60 kg (132 lbs).

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have had weight loss surgery.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ predose on day 1 through week 20

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~predose on day 1 through week 20

This trial's timeline: 3 weeks for screening, Varies for treatment, and predose on day 1 through week 20 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs), and Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug Administration

Secondary study objectives

PD: Change from Baseline in AUC of Acetaminophen to Assess the Delay in Gastric Emptying

PD: Change from Baseline in AUC of Glucose

PD: Change from Baseline in Cmax of Acetaminophen to Assess the Delay in Gastric Emptying

+8 more